EXPERIENCE & REASON |
a Department of Pediatrics
b Saul Krugman Division of Infectious Diseases and Immunology
c Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York
d Division of Infectious Diseases, Department of Pediatrics, Columbia University Medical Center, New York, New York
ABSTRACT
In March 1995, the US Food and Drug Administration approved a live attenuated varicella vaccine for use in healthy children 12 months to 12 years old. We report here an 18-month-old girl with cell-mediated immunodeficiency who developed a severe vaccine-associated rash and clinical evidence of vaccine-associated pneumonia 1 month after inadvertent receipt of varicella vaccine.
Key Words: varicella vaccine adverse reaction immunodeficiency
Abbreviations: LAVV, live attenuated varicella vaccine Ig, immunoglobulin PCR, polymerase chain reaction VZV, varicella-zoster virus WT, wild type